Coronavirus Information: Vaccinations | Testing | Safety Policies & Visitor Guidelines | Appointments & Scheduling | FAQs

Penn Medicine Multiple Myeloma Program

Doctor at desk talking to patient

Program Overview

At Penn Medicine’s Abramson Cancer Center, our clinicians and researchers are leading the way in the diagnosis and treatment of multiple myeloma.

Today, there is more hope than ever for those diagnosed with multiple myeloma. Our Multiple Myeloma Program, led by Edward Stadtmauer MD, is the largest program in the Delaware Valley and one of the largest in the nation with highly experienced teams of multiple myeloma specialists. 

By putting our experience to work, we offer the best possible treatment outcomes.

Why Penn's Multiple Myeloma Program is Different

Our Multiple Myeloma Program is unique in many ways, offering:

  • One of the few hematologic malignancy research programs in the country that is approved and funded by the National Cancer Institute
  • Nationally recognized experts with extensive experience in multiple myeloma
  • Coordinated care by a multidisciplinary team that includes physician specialists in integrative medicine and wellness, surgery, medical oncology, radiation oncology, pathology and radiology
  • Advanced diagnostic testing, treatments and technologies
  • Support services and education programs
  • A reputation for sensitivity and responsiveness
  • Personalized attention
  • Innovative clinical trials

A Premier Research Program

Our multiple myeloma clinicians and researchers have dedicated their clinical and research careers to improving our ability to diagnose and treat patients with multiple myeloma.

Program highlights include:

  • We have pioneered new therapies for the treatment of multiple myeloma by translating the latest developments in drug discovery and laboratory into treatment approaches.
  • Our doctors designed trials sponsored by the National Cancer Institute and conducted by major medical centers nationwide. The results of these clinical trials prompted major changes in practice that reverberated throughout the nation.
  • In 1992, the Program was designated a Research Center for the International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry (now know as the CIBMTR). Our faculty hold high-level administrative positions in this NIH funded international research effort.
  • In 1999, the Program was awarded the designation of Transplant Center for the National Marrow Donor Program opening the potentially lifesaving therapy of bone marrow transplant to patients without sibling donors.

Treatments and Services Offered by the Multiple Myeloma Program

We offer the most advanced treatments and therapies, as well as support, for anyone diagnosed with myeloma, including: